Your browser is no longer supported. Please, upgrade your browser.
Settings
CBAY CymaBay Therapeutics, Inc. daily Stock Chart
CBAY [NASD]
CymaBay Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.30% Shs Outstand56.54M Perf Week-5.33%
Market Cap682.44M Forward P/E- EPS next Y-0.94 Insider Trans-85.91% Shs Float56.54M Perf Month-0.66%
Income-27.60M PEG- EPS next Q-0.14 Inst Own59.30% Short Float4.36% Perf Quarter12.49%
Sales10.00M P/S68.24 EPS this Y30.60% Inst Trans0.51% Short Ratio1.89 Perf Half Y48.28%
Book/sh1.93 P/B6.25 EPS next Y-1.10% ROA-43.60% Target Price20.63 Perf Year230.68%
Cash/sh1.72 P/C7.01 EPS next 5Y- ROE-60.30% 52W Range3.16 - 15.59 Perf YTD31.20%
Dividend- P/FCF- EPS past 5Y17.70% ROI-23.40% 52W High-21.87% Beta1.93
Dividend %- Quick Ratio6.30 Sales past 5Y26.80% Gross Margin- 52W Low285.44% ATR0.96
Employees26 Current Ratio6.30 Sales Q/Q- Oper. Margin- RSI (14)44.84 Volatility6.41% 7.83%
OptionableYes Debt/Eq0.07 EPS Q/Q61.40% Profit Margin- Rel Volume0.34 Prev Close12.07
ShortableYes LT Debt/Eq0.04 EarningsMar 15 AMC Payout- Avg Volume1.30M Price12.18
Recom1.80 SMA20-1.33% SMA50-8.65% SMA20027.60% Volume312,475 Change0.91%
Feb-13-18Initiated Evercore ISI Outperform
Jan-25-18Resumed ROTH Capital Buy $27
Jan-24-18Reiterated H.C. Wainwright Buy $12 → $18
Aug-23-17Initiated Leerink Partners Outperform $12
Aug-18-17Initiated SunTrust Buy $15
Jul-20-17Reiterated Oppenheimer Outperform $8 → $15
Jun-23-17Initiated Oppenheimer Outperform $8
Jan-30-17Upgrade H.C. Wainwright Neutral → Buy $2.50 → $6
Jan-04-17Reiterated H.C. Wainwright Neutral $1.50 → $2.50
Jun-01-16Downgrade H.C. Wainwright Buy → Neutral $2.25
Sep-08-15Initiated H.C. Wainwright Buy $12
Jul-21-15Initiated Piper Jaffray Overweight $4
May-08-15Reiterated Stifel Buy $15 → $9
Jan-20-15Reiterated Stifel Buy $10 → $15
Apr-20-18 08:25AM  Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Offshore Services, and Sprouts Farmers Market Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-13-18 07:30AM  Wired News CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018 ACCESSWIRE
Apr-12-18 09:37AM  CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics ACCESSWIRE
Apr-11-18 04:29PM  Could This Tiny Biotech Rout Intercept In Liver Disease Drugs? Investor's Business Daily +11.35%
07:47AM  CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018 GlobeNewswire
Apr-09-18 12:05PM  5 Small-Cap Stocks With Explosive Upside Potential TheStreet.com
Mar-15-18 04:01PM  CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update GlobeNewswire -8.09%
12:15PM  CymaBay Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-09-18 11:02AM  High Growth Stocks To Invest In Simply Wall St.
Mar-06-18 08:00AM  CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15 GlobeNewswire
Mar-05-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March GlobeNewswire
Feb-16-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Sunrun, CymaBay Therapeutics, Arrow Electronics, MGM Resorts International, Celanese, and Motorola Solutions Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-14-18 11:18AM  4 charts to watch as tech stocks rebound MarketWatch
Feb-06-18 08:00AM  CymaBay Therapeutics to Participate in Investor Conferences in February GlobeNewswire
Feb-01-18 04:01PM  CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
11:02AM  High Growth Stocks To Invest In Simply Wall St.
Jan-30-18 08:00AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire +6.29%
Jan-29-18 04:44PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-08-18 08:00AM  Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis GlobeNewswire
08:00AM  CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America GlobeNewswire
Jan-02-18 04:01PM  CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-17 12:23PM  BlackBerry Among Four Stocks Breaking Out Forbes
Dec-08-17 01:21PM  7 Strong Buy Disruptive Stocks You Should Track Now InvestorPlace
Dec-04-17 11:18AM  CymaBay Therapeutics, Inc. Value Analysis (NASDAQ:CBAY) : December 4, 2017 Capital Cube
08:00AM  CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel GlobeNewswire
Dec-01-17 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within MGM Resorts International, Celanese, Motorola Solutions, Sunrun, CymaBay Therapeutics, and Arrow Electronics New Research Emphasizes Economic Growth GlobeNewswire
07:12AM  CymaBay Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CBAY-US : December 1, 2017 Capital Cube
Nov-13-17 08:00AM  CymaBay Therapeutics to Present at Three Investor Conferences GlobeNewswire -9.14%
Nov-08-17 04:01PM  CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates GlobeNewswire
01:00PM  CymaBay Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-01-17 08:30AM  CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8 GlobeNewswire
Oct-31-17 08:00AM  CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer GlobeNewswire
Oct-25-17 11:12AM  Harry Boxers momentum stocks to watch this week MarketWatch
Oct-23-17 04:30PM  CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis GlobeNewswire
Oct-09-17 08:00AM  CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting GlobeNewswire
Sep-18-17 08:00AM  CymaBay Therapeutics to Present at Two Investor Conferences GlobeNewswire
Sep-12-17 12:50PM  Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning InvestorPlace +7.34%
Sep-11-17 08:00AM  CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis GlobeNewswire +5.38%
Aug-15-17 08:30AM  CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology GlobeNewswire
Aug-10-17 04:01PM  CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-17 08:33AM  Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season Zacks
Aug-07-17 08:00AM  CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10 GlobeNewswire
Jul-24-17 04:05PM  CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-20-17 08:15AM  Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2% Zacks
Jul-19-17 11:34AM  Oppenheimer Bullish on Bank of America Corp (BAC), CymaBay Therapeutics Inc (CBAY) and TherapeuticsMD Inc (TXMD); Heres Why SmarterAnalyst +6.20%
08:30AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jul-18-17 08:10AM  Today's Research Reports on Stocks to Watch: Editas Medicine and Cymabay Therapeutics Accesswire +16.05%
Jul-17-17 04:15PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire +5.84%
10:16AM  H.C. Wainwright Boosts Price Target on CymaBay Therapeutics Inc (CBAY) SmarterAnalyst
07:30AM  CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis GlobeNewswire
Jul-13-17 08:36AM  Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options Zacks +6.62%
Jul-03-17 09:28AM  New Analyst Coverage Make These 5 Stocks Worth a Bet Zacks
Jun-30-17 04:09PM  Penny Stocks to Watch for July 2017 Investopedia
Jun-26-17 08:00AM  CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance GlobeNewswire
May-11-17 04:01PM  CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
03:00PM  Investor Network: CymaBay Therapeutics, Inc. to Host Earnings Call Accesswire
May-04-17 08:00AM  CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11 GlobeNewswire
Apr-13-17 08:00AM  CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 GlobeNewswire
Mar-30-17 08:00AM  CymaBay Therapeutics to Present at Two Investor Conferences in April GlobeNewswire
Mar-29-17 01:04PM  CYMABAY THERAPEUTICS, INC. Financials
08:02AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:00AM  CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. GlobeNewswire
Mar-23-17 04:01PM  CymaBay Reports Fourth Quarter and Year End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 CymaBay Therapeutics Inc Earnings Release - Time Not Supplied
Mar-16-17 04:48PM  CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23 GlobeNewswire
Mar-15-17 10:37AM  Will Cymabay Therapeutics (CBAY) Continue to Surge Higher? Zacks
Mar-09-17 08:00AM  CymaBay Therapeutics to Present at Two Investor Conferences in March GlobeNewswire +20.29%
Mar-08-17 09:30AM  Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro Zacks
Mar-07-17 02:41PM  Explosive Stocks Under $10 Zacks
Feb-22-17 09:30AM  The Zacks Analyst Blog Highlights: Cymabay Therapeutics, Attunity, Lumentum Holdings, Datawatch and Arconic Zacks
Feb-21-17 05:34PM  5 Top Performers of Trump's First 30 Days in Office Zacks
Feb-14-17 10:28AM  Can The Uptrend Continue for Cymabay Therapeutics (CBAY)?
Feb-13-17 09:40AM  Cerner's EHR Platform to Enhance Health Care at San Juan NGO
Feb-10-17 08:49AM  5 Breakout Stocks for Superior Returns +5.38%
Feb-09-17 08:30AM  Cymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher
Feb-07-17 08:00AM  CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-03-17 04:07PM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-02-17 09:15AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire
Feb-01-17 04:01PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire +11.83%
Jan-30-17 07:02AM  CymaBay Therapeutics upgraded by H.C. Wainwright +10.18%
Jan-24-17 06:15AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-05-17 08:00AM  CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate GlobeNewswire
06:04AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-04-17 12:15PM  Wednesdays Top 5 Biopharma Movers +21.05%
11:00AM  Taking A Look At CymaBay Therapeutics Inc (CBAY)s Big Deal at Insider Monkey
08:10AM  Heres Why Apple, Tesla, and Three Other Stocks Are Trending at Insider Monkey
Jan-03-17 04:01PM  CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States GlobeNewswire +9.83%
Dec-16-16 07:54PM  Pain Therapeutics, Inc. (PTIE): How Does It Compare Against Its Peers? at Insider Monkey
Dec-08-16 08:01AM  CYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -13.71%
08:00AM  CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors GlobeNewswire
Dec-07-16 08:00AM  CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis GlobeNewswire
Dec-06-16 04:10PM  Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy GlobeNewswire
08:00AM  CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar GlobeNewswire
Nov-28-16 08:00AM  CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-10-16 04:01PM  CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City GlobeNewswire +5.52%
08:00AM  CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis GlobeNewswire
Nov-09-16 04:05PM  CYMABAY THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report +13.28%
04:01PM  CymaBay Reports Third Quarter 2016 Financial Results GlobeNewswire
08:00AM  CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC) GlobeNewswire
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDFISCHER CARLDirectorMar 22Option Exercise5.1915,00077,83015,000Mar 23 04:56 PM
GOLDFISCHER CARLDirectorMar 22Sale13.0315,000195,3750Mar 23 04:56 PM
EMSTER KURT VONDirectorMar 05Sale15.5113,353207,105273,417Mar 07 04:19 PM
EMSTER KURT VONDirectorFeb 15Sale14.4968,712995,637286,770Feb 20 04:08 PM
EMSTER KURT VONDirectorFeb 14Sale16.69162,9792,720,120355,482Feb 15 04:12 PM
EMSTER KURT VONDirectorFeb 13Sale13.5155,078744,104518,461Feb 15 04:12 PM
EMSTER KURT VONDirectorFeb 07Sale12.3540,763503,423419,693Feb 09 04:17 PM
EMSTER KURT VONDirectorFeb 05Sale12.1418,831228,608460,456Feb 07 04:20 PM
EMSTER KURT VONDirectorFeb 02Sale12.112,00024,220479,287Feb 05 04:07 PM
EMSTER KURT VONDirectorFeb 01Sale12.1588,0981,070,391481,287Feb 05 04:07 PM
EMSTER KURT VONDirectorJan 31Sale12.2312,300150,429569,385Feb 01 04:29 PM
EMSTER KURT VONDirectorJan 30Sale12.2285,3391,042,843581,685Feb 01 04:29 PM
EMSTER KURT VONDirectorJan 25Sale12.1839,438480,355667,024Jan 26 08:40 PM
EMSTER KURT VONDirectorJan 22Sale10.40138,2531,437,831706,462Jan 24 04:02 PM
EMSTER KURT VONDirectorJan 19Sale10.25130,5841,338,486844,715Jan 22 05:26 PM
EMSTER KURT VONDirectorJan 18Sale10.2113,632139,183975,299Jan 22 05:26 PM
EMSTER KURT VONDirectorJan 05Sale10.214,30043,903988,931Jan 09 04:34 PM
EMSTER KURT VONDirectorDec 22Sale9.41173,1921,629,304993,231Dec 27 04:08 PM
EMSTER KURT VONDirectorNov 10Sale9.2650,048463,3791,166,423Nov 14 05:48 PM
GOLDFISCHER CARLDirectorNov 02Option Exercise2.3518,00042,21018,000Nov 06 08:45 PM
McWherter CharlesSVP & Chief Scientific OfficerNov 02Buy8.675,00043,34115,000Nov 06 08:43 PM
GOLDFISCHER CARLDirectorNov 02Sale8.6618,000155,8800Nov 06 08:45 PM
EMSTER KURT VONDirectorNov 01Sale9.254,32039,9791,216,471Nov 03 04:52 PM
EMSTER KURT VONDirectorOct 31Sale9.2752,573487,3521,220,791Nov 01 04:39 PM
EMSTER KURT VONDirectorOct 30Sale9.266,63661,4491,273,364Nov 01 04:39 PM
EMSTER KURT VONDirectorOct 03Sale7.8170,940554,0411,280,000Oct 04 04:02 PM
EMSTER KURT VONDirectorOct 02Sale7.9337,936300,8321,350,940Oct 04 04:02 PM
EMSTER KURT VONDirectorSep 29Sale8.04120,735970,7091,388,876Oct 02 05:20 PM
EMSTER KURT VONDirectorSep 28Sale8.1590,389736,6701,509,611Oct 02 05:20 PM
Wills Robert JamesDirectorAug 01Buy6.845,00034,22130,000Aug 02 08:21 AM
McWherter CharlesSVP & Chief Scientific OfficerJul 20Buy7.435,00037,13710,000Jul 24 06:19 AM
Shah SujalInterim President & CEOJul 20Buy7.3410,00073,40185,000Jul 24 06:15 AM
EMSTER KURT VONDirectorJul 19Buy6.50153,846999,9991,753,846Feb 12 04:09 PM